LUDWIG, Heinz, Hedwig KASPARU, Clemens LEITGEB, Elisabeth RAUCH, Werner LINKESCH, Niklas ZOJER, Richard GREIL, Adelheid SEEBACHER, Luděk POUR, Adalbert WEISSMANN and Zdeněk ADAM. Bendamustine-Bortezomib-Dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. WASHINGTON: American Society of Hematology, 2014, vol. 123, No 7, p. 985-991. ISSN 0006-4971. Available from: https://dx.doi.org/10.1182/blood-2013-08-521468.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Bendamustine-Bortezomib-Dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma
Authors LUDWIG, Heinz (40 Austria), Hedwig KASPARU (40 Austria), Clemens LEITGEB (40 Austria), Elisabeth RAUCH (40 Austria), Werner LINKESCH (40 Austria), Niklas ZOJER (40 Austria), Richard GREIL (40 Austria), Adelheid SEEBACHER (40 Austria), Luděk POUR (203 Czech Republic, belonging to the institution), Adalbert WEISSMANN (40 Austria) and Zdeněk ADAM (203 Czech Republic, guarantor, belonging to the institution).
Edition Blood, WASHINGTON, American Society of Hematology, 2014, 0006-4971.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 10.452
RIV identification code RIV/00216224:14110/14:00074902
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1182/blood-2013-08-521468
UT WoS 000335836700013
Keywords in English Bendamustine; bortezomib; dexamethasone; relapsed/refractory myeloma
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 2/7/2014 17:08.
Abstract
Bendamustine with bortezomib and dexamethasone was evaluated in 79 patients with relapsed/refractory multiple myeloma. Median age was 64 (range 40-80) years and patients had a median of 2 (range 1-6) prior treatment lines. Bendamustine 70 mg/m2, day 1 and 4, bortezomib 1.3mg/m2 days 1, 4, 8, 11 intravenously, and dexamethasone 20 mg, days 1, 4, 8, and 11, q 28 days, was given for up to 8 cycles. Primary endpoint was response rate (ORR) and secondary endpoints were progression-free survival (PFS), overall survival (OS), time to response and toxicity. ORR was 60.9%, and when minor responses were included, 75.9%. Median time to response was 31 days (111 to best response). ORR rate was similar in patients previously exposed to bortezomib, lenalidomide and to both bortezomib and lenalidomide. PFS was 9.7 and OS 25.6 months. Multivariate analysis showed high LDH, >/-3 prior treatment lines and low platelet counts correlating with short survival. Grade 3/4 thrombopenia and G 3/4/5 infections were noted in 38% and 23% respectively. Grade
PrintDisplayed: 17/10/2024 11:23